MX2021010066A - Formulaciones agradables al paladar. - Google Patents
Formulaciones agradables al paladar.Info
- Publication number
- MX2021010066A MX2021010066A MX2021010066A MX2021010066A MX2021010066A MX 2021010066 A MX2021010066 A MX 2021010066A MX 2021010066 A MX2021010066 A MX 2021010066A MX 2021010066 A MX2021010066 A MX 2021010066A MX 2021010066 A MX2021010066 A MX 2021010066A
- Authority
- MX
- Mexico
- Prior art keywords
- animal
- soft chewable
- animal based
- veterinary
- based palatant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962807871P | 2019-02-20 | 2019-02-20 | |
| PCT/US2020/018762 WO2020172232A1 (en) | 2019-02-20 | 2020-02-19 | Palatable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010066A true MX2021010066A (es) | 2021-09-21 |
Family
ID=69960719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010066A MX2021010066A (es) | 2019-02-20 | 2020-02-19 | Formulaciones agradables al paladar. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12115162B2 (uk) |
| EP (1) | EP3927315A1 (uk) |
| JP (1) | JP7442540B2 (uk) |
| CN (1) | CN113438941A (uk) |
| AU (1) | AU2020224102C1 (uk) |
| BR (1) | BR112021016480A2 (uk) |
| CA (1) | CA3127621C (uk) |
| CL (1) | CL2021002192A1 (uk) |
| CO (1) | CO2021010698A2 (uk) |
| EC (1) | ECSP21059181A (uk) |
| IL (1) | IL285078A (uk) |
| MA (1) | MA55027A (uk) |
| MX (1) | MX2021010066A (uk) |
| UA (1) | UA126843C2 (uk) |
| WO (1) | WO2020172232A1 (uk) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202122077A (zh) * | 2019-09-06 | 2021-06-16 | 美商拜耳保健責任有限公司 | 適口軟咀嚼物 |
| CN114727622A (zh) * | 2019-09-06 | 2022-07-08 | 礼蓝美国公司 | 适口颗粒状兽用药组合物 |
| WO2023198476A1 (en) * | 2022-04-15 | 2023-10-19 | Krka, D.D., Novo Mesto | Soft chewable veterinary dosage form |
| JP7355175B1 (ja) | 2022-07-25 | 2023-10-03 | フジテック株式会社 | エレベータのブレーキ制動能力検査方法及びブレーキ制動能力検査装置 |
| FR3138315A1 (fr) | 2022-07-27 | 2024-02-02 | Virbac | Produit à usage vétérinaire et procédé pour sa fabrication |
| WO2024133631A1 (en) | 2022-12-22 | 2024-06-27 | Krka, D.D., Novo Mesto | Veterinary composition comprising oclacitinib |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2623976B1 (fr) * | 1987-12-08 | 1994-02-25 | So Ge Val | Comprime pour animal domestique |
| WO2003000177A2 (en) | 2001-06-21 | 2003-01-03 | Andrx Pharmaceuticals, Inc. | Stable controlled release pharmaceutical compositions containing pravastatin |
| MXPA05001727A (es) | 2002-08-13 | 2006-03-10 | Akzo Nobel Nv | Composiciones y proceso para suministrar un aditivo. |
| US20040037869A1 (en) | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
| TWI366442B (en) | 2003-07-30 | 2012-06-21 | Novartis Ag | Palatable ductile chewable veterinary composition |
| BRPI0610965A2 (pt) | 2005-06-01 | 2011-02-22 | Hills Pet Nutrition Inc | composição para consumo por um animal, métodos para melhorar a palatabilidade de uma composição para consumo por um animal, para aumentar a frequência de ingestão ou a taxa de ingestão de uma composição para consumo por um animal, e para fabricar uma composição para consumo animal, produto, kit, e, meios para comunicar informação sobre ou instruções para misturar e administrar uma composição para consumo animal tendo melhorada palatabilidade a um animal |
| US7955632B2 (en) * | 2005-12-07 | 2011-06-07 | Bayer B.V. | Process for manufacturing chewable dosage forms for drug delivery and products thereof |
| US20070128251A1 (en) | 2005-12-07 | 2007-06-07 | Piedmont Pharmaceuticals, Inc. | Process for manufacturing chewable dosage forms for drug delivery and products thereof |
| EP2063869B1 (en) | 2006-09-07 | 2014-03-05 | Merial Ltd. | Soft chewable veterinary antibiotic formulations |
| BRPI0917459B1 (pt) | 2008-08-20 | 2017-09-12 | Zoetis Services Llc | N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide |
| WO2013037650A1 (fr) * | 2011-09-15 | 2013-03-21 | Friulchem Spa | Compositions pour administration orale aux animaux, leurs procedes d'obtention et leurs utilisations |
| CA2883139C (fr) | 2012-08-31 | 2021-08-10 | Friulchem Spa | Compositions pour administration orale aux animaux, leurs procedes d'obtention et leurs utilisations |
| US9532946B2 (en) | 2012-11-20 | 2017-01-03 | Intervet Inc. | Manufacturing of semi-plastic pharmaceutical dosage units |
| BR112016011111B1 (pt) | 2013-12-04 | 2022-11-16 | Boehringer Ingelheim Vetmedica Gmbh | Composições farmacêuticas aprimoradas de pimobendan |
| WO2016073347A1 (en) | 2014-11-03 | 2016-05-12 | Zoetis Services Llc | Palatable chewable veterinary composition |
| US10434061B2 (en) | 2014-12-05 | 2019-10-08 | Societe Des Produits Nestle S.A. | Composition and method for orally administering one or more active agents to a pet |
| EP3389628A4 (en) | 2015-12-19 | 2019-08-07 | Dixit, Manesh A. | PHARMACEUTICAL FORMULATIONS OF MOUSE CHEESE TABLETS |
-
2020
- 2020-02-19 JP JP2021549085A patent/JP7442540B2/ja active Active
- 2020-02-19 CA CA3127621A patent/CA3127621C/en active Active
- 2020-02-19 MA MA055027A patent/MA55027A/fr unknown
- 2020-02-19 WO PCT/US2020/018762 patent/WO2020172232A1/en active Application Filing
- 2020-02-19 BR BR112021016480-4A patent/BR112021016480A2/pt unknown
- 2020-02-19 US US17/421,533 patent/US12115162B2/en active Active
- 2020-02-19 MX MX2021010066A patent/MX2021010066A/es unknown
- 2020-02-19 CN CN202080015345.8A patent/CN113438941A/zh active Pending
- 2020-02-19 UA UAA202104565A patent/UA126843C2/uk unknown
- 2020-02-19 EP EP20714040.1A patent/EP3927315A1/en active Pending
- 2020-02-19 AU AU2020224102A patent/AU2020224102C1/en active Active
-
2021
- 2021-07-22 IL IL285078A patent/IL285078A/en unknown
- 2021-08-11 EC ECSENADI202159181A patent/ECSP21059181A/es unknown
- 2021-08-13 CO CONC2021/0010698A patent/CO2021010698A2/es unknown
- 2021-08-18 CL CL2021002192A patent/CL2021002192A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020172232A1 (en) | 2020-08-27 |
| MA55027A (fr) | 2021-12-29 |
| CA3127621C (en) | 2024-05-14 |
| JP2022521245A (ja) | 2022-04-06 |
| CN113438941A (zh) | 2021-09-24 |
| EP3927315A1 (en) | 2021-12-29 |
| AU2020224102C1 (en) | 2023-03-16 |
| AU2020224102B2 (en) | 2022-09-08 |
| CL2021002192A1 (es) | 2022-04-01 |
| UA126843C2 (uk) | 2023-02-08 |
| IL285078A (en) | 2021-09-30 |
| JP7442540B2 (ja) | 2024-03-04 |
| US20220062287A1 (en) | 2022-03-03 |
| NZ779157A (en) | 2023-10-27 |
| AU2020224102A1 (en) | 2021-08-19 |
| ECSP21059181A (es) | 2021-11-30 |
| CA3127621A1 (en) | 2020-08-27 |
| US12115162B2 (en) | 2024-10-15 |
| CO2021010698A2 (es) | 2021-08-30 |
| KR20210114978A (ko) | 2021-09-24 |
| BR112021016480A2 (pt) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010066A (es) | Formulaciones agradables al paladar. | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| MX2022000027A (es) | Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales. | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2023009682A (es) | Inhibidores de tyk2 y sus usos. | |
| NZ737536A (en) | Substituted benzamides and methods of use thereof | |
| PH12019501900A1 (en) | Treatment of hidradenitis suppurativa | |
| WO2021239935A9 (en) | Neutralizing antibodies against sars-related coronavirus | |
| WO2005086814A3 (en) | Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3) | |
| EP4121019A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF NON-MALIGNANT RESPIRATORY DISEASE | |
| MX2023009723A (es) | Inhibidores de tyk2 y sus usos. | |
| CR20210587A (es) | Inhibidores de molécula pequeña de quinasa inductora de nf-kb | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| WO2020068950A8 (en) | Hdac1,2 inhibitors | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2022004382A (es) | Metodos para promover la produccion de scfa por microbiota intestinal. | |
| MX2023001721A (es) | Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer. | |
| MX2020012622A (es) | Tratamientos. | |
| MX2024003859A (es) | Inhibidores de lpxc y usos de estos. | |
| MX2023012442A (es) | Inhibidores de la ferroportina modificados. | |
| MX2023003725A (es) | Composiciones farmacéuticas y usos de las mismas para la prevención y/o tratamiento de la inflamación. |